CompletedNCT00302744
Psilocybin or niacin for anxiety and depression in advanced cancer
About this title
Read the official source — NCT00302744Medication studyAges 18–70United States
Understand this study
Who was this study for?
This study was for people with anxiety. Listed age limits: 18 years to 70 years. Other eligibility criteria applied.
- Listed locations
- TorranceSee all locations and recruitment
- Study phase
- Phase 1 / Phase 2This study spans more than one phase, so it may combine goals such as safety, dosing, and early effectiveness.
Study information
Study start dateApril 2004
- Recruitment status
- Completed
- Enrollment listed in the registry
- 12
- Sponsor
- Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
- Sponsor type
- Hospital / academic medical center
- Study type
- Drug
- Intervention type
- Diagnostic test, Drug, Other
- Study phase
- Phase 1 / Phase 2This study spans more than one phase, so it may combine goals such as safety, dosing, and early effectiveness.
- Locations
- United States
- Age range
- From 18 Years to 70 Years
- Official registry ID
- NCT00302744
- Official title
Show the full official title
Effects of Psilocybin in Advanced-Stage Cancer Patients With Anxiety
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Torrance
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center, a hospital or academic medical center.
Did this study involve medication?
Yes. The study involved medication, including Psilocybin (drug).
Who was this study for?
This study was for people with anxiety. Listed age limits: 18 years to 70 years. Other eligibility criteria applied.
